Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Peters S, et al. Among authors: swalduz a. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. Nat Med. 2024. PMID: 38898120 Free PMC article. Clinical Trial.
Survival of bronchopulmonary cancers according to radon exposure.
Dessemon J, Perol O, Chauvel C, Noelle H, Coudon T, Grassot L, Foray N, Belladame E, Fayette J, Fournie F, Swalduz A, Neidhart EM, Saintigny P, Tabutin M, Boussageon M, Gomez F, Avrillon V, Perol M, Charbotel B, Fervers B. Dessemon J, et al. Among authors: swalduz a. Front Public Health. 2024 Jan 24;11:1306455. doi: 10.3389/fpubh.2023.1306455. eCollection 2023. Front Public Health. 2024. PMID: 38328545 Free PMC article.
Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers.
Albaret MA, Paré A, Malet L, De Souza G, Lavergne E, Goga D, De Pinieux G, Castellier C, Swalduz A, Robin V, Lavergne V, Mertani HC, Treilleux I, Vermot-Desroches C, Diaz JJ, Saintigny P. Albaret MA, et al. Among authors: swalduz a. Transl Oncol. 2021 Jan;14(1):100878. doi: 10.1016/j.tranon.2020.100878. Epub 2020 Sep 30. Transl Oncol. 2021. PMID: 33010552 Free PMC article.
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-Cuaran S; BOLERO Consortium. Tabbò F, et al. Among authors: swalduz a. Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31. Cancer Treat Rev. 2022. PMID: 35033867 Review.
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, Curcio H, Du Rusquec P, Cortot AB, Gounant V, Abbar B, Duchemann B, Giroux-Leprieur E, Pierret T, Quilot FM, Cadranel J, Fallet V. Mehlman C, et al. Among authors: swalduz a. Oncologist. 2024 Dec 26:oyae312. doi: 10.1093/oncolo/oyae312. Online ahead of print. Oncologist. 2024. PMID: 39724403 Free article.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.
Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, Nicotra C, Auclin E, Remon J, Morris C, Green E, Massard C, Pérol M, Friboulet L, Besse B, Saintigny P. Mezquita L, et al. Among authors: swalduz a. JCO Precis Oncol. 2020 Apr 2;4:PO.19.00281. doi: 10.1200/PO.19.00281. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923908 Free PMC article.
51 results